(NASDAQ: IMUX) Immunic's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 70.9%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 40.5%.
Immunic's earnings in 2026 is -$103,047,000.On average, 10 Wall Street analysts forecast IMUX's earnings for 2026 to be -$45,082,715, with the lowest IMUX earnings forecast at -$78,978,950, and the highest IMUX earnings forecast at -$22,986,411. On average, 7 Wall Street analysts forecast IMUX's earnings for 2027 to be -$55,523,429, with the lowest IMUX earnings forecast at -$62,475,886, and the highest IMUX earnings forecast at -$42,941,646.
In 2028, IMUX is forecast to generate -$15,456,587 in earnings, with the lowest earnings forecast at -$60,118,305 and the highest earnings forecast at $92,198,241.